{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:34:06Z","timestamp":1768473246783,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00120-024-02505-1","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:29:35Z","timestamp":1737476975000},"page":"229-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapiealgorithmus nach Versagen der Erstlinientherapie beim metastasierten Prostatakarzinom","Treatment algorithm following first-line therapy failure in metastatic prostate cancer"],"prefix":"10.1007","volume":"64","author":[{"given":"Christian","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"37","key":"2505_CR1","first-page":"622","volume":"119","author":"AS Merseburger","year":"2022","unstructured":"Merseburger\u00a0AS, Krabbe\u00a0LM, Krause\u00a0BJ, Bohmer\u00a0D, Perner\u00a0S, Amsberg\u00a0GV (2022) The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma. Dtsch \u00c4rztebl Int 119(37):622\u2013632","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2505_CR2","first-page":"043","volume":"2024","author":"Deutsche Krebsgesellschaft","year":"2024","unstructured":"Deutsche Krebsgesellschaft (2024) AWMF 2024:43\u201322O","journal-title":"AWMF"},{"issue":"12","key":"2505_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, de Bono\u00a0J, Chi\u00a0KN, Fizazi\u00a0K, Herrmann\u00a0K, Rahbar\u00a0K et\u00a0al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"key":"2505_CR4","doi-asserted-by":"crossref","unstructured":"Rajwa P, Zapala P, Merseburger AS (2024) Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer. Eur Urol Focus","DOI":"10.1016\/j.euf.2024.07.012"},{"issue":"1","key":"2505_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00345-024-05280-y","volume":"42","author":"A Bahl","year":"2024","unstructured":"Bahl\u00a0A, Sodatonou\u00a0H, Snjider\u00a0R, Chilelli\u00a0A, Pranzo\u00a0A, Martins\u00a0K et\u00a0al (2024) Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type\u00a02 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study. World J Urol 42(1):584","journal-title":"World J Urol"},{"key":"2505_CR6","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND et\u00a0al (2024) Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol"},{"issue":"4","key":"2505_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41585-022-00680-4","volume":"20","author":"P Rajwa","year":"2023","unstructured":"Rajwa\u00a0P, Quhal\u00a0F, Pradere\u00a0B, Gandaglia\u00a0G, Ploussard\u00a0G, Leapman\u00a0MS et\u00a0al (2023) Prostate cancer risk, screening and management in patients with germline BRCA\u00a01\/2 mutations. Nat Rev Urol 20(4):205\u2013216","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2505_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/a-2266-3607","volume":"55","author":"G von Amsberg","year":"2024","unstructured":"von Amsberg\u00a0G, Paulsen\u00a0FO (2024) Molecular testing of prostate cancer: timing, methods and consequences. Aktuelle Urol 55(2):123\u2013133","journal-title":"Aktuelle Urol"},{"issue":"3","key":"2505_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker\u00a0C, Nilsson\u00a0S, Heinrich\u00a0D, Helle\u00a0SI, O\u2019Sullivan\u00a0JM, Fossa\u00a0SD et\u00a0al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N\u00a0Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"3","key":"2505_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith\u00a0M, Parker\u00a0C, Saad\u00a0F, Miller\u00a0K, Tombal\u00a0B, Ng\u00a0QS et\u00a0al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet Oncol 20(3):408\u2013419","journal-title":"Lancet Oncol"},{"key":"2505_CR11","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2011\/20110905108630\/anx_108630_de.pdf"},{"key":"2505_CR12","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240419162450\/anx_162450_de.pdf"},{"key":"2505_CR13","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210416151645\/anx_151645_de.pdf"},{"key":"2505_CR14","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240125161756\/anx_161756_de.pdf"},{"key":"2505_CR15","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240105161305\/anx_161305_de.pdf"},{"key":"2505_CR16","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230419158798\/anx_158798_de.pdf"},{"key":"2505_CR17","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20221209157605\/anx_157605_de.pdf"},{"key":"2505_CR18","unstructured":"Stand 22.11.2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170403137509\/anx_137509_de.pdf"},{"issue":"12","key":"2505_CR19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf\u00a0DJ, Annala\u00a0M, Taavitsainen\u00a0S, Finch\u00a0DL, Oja\u00a0C, Vergidis\u00a0J et\u00a0al (2019) Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a\u00a0multicentre, randomised, open-label, phase\u00a02, crossover trial. Lancet Oncol 20(12):1730\u20131739","journal-title":"Lancet Oncol"},{"issue":"4","key":"2505_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","volume":"71","author":"JS de Bono","year":"2017","unstructured":"de Bono\u00a0JS, Smith\u00a0MR, Saad\u00a0F, Rathkopf\u00a0DE, Mulders\u00a0PFA, Small\u00a0EJ et\u00a0al (2017) Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol 71(4):656\u2013664","journal-title":"Eur Urol"},{"issue":"11","key":"2505_CR21","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S1470-2045(22)00560-5","volume":"23","author":"AS Merseburger","year":"2022","unstructured":"Merseburger\u00a0AS, Attard\u00a0G, Astrom\u00a0L, Matveev\u00a0VB, Bracarda\u00a0S, Esen\u00a0A et\u00a0al (2022) Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase\u00a03b\u00a0study. Lancet Oncol 23(11):1398\u20131408","journal-title":"Lancet Oncol"},{"issue":"19","key":"2505_CR22","first-page":"4318","volume":"30","author":"M Hussain","year":"2024","unstructured":"Hussain\u00a0M, Kocherginsky\u00a0M, Agarwal\u00a0N, Adra\u00a0N, Zhang\u00a0J, Paller\u00a0CJ et\u00a0al (2024) Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin. Cancer Res 30(19):4318\u20134328","journal-title":"Cancer Res"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02505-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:52:12Z","timestamp":1741629132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02505-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02505-1","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"12 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Thomas weist auf folgende Beziehungen hin: Vortragshonorare: Apogepha, AstraZeneca, Astellas, Bayer, Ferring Ipsen, MSD, Merck Serono, Janssen, Pfizer. Beratert\u00e4tigkeit: Apogepha, Astellas, Bayer, Janssen. Forschungsf\u00f6rderung und Studien:AstraZeneca, Bayer, MSD, Janssen, Pfizer. A.\u00a0S.\u00a0Merseburger weist auf folgende Beziehungen hin: Vortragshonorare: Ambu, Amgen, Apogepha, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Farco, Ferring Ipsen, Hexal, Sandoz, MedUpdate, MSD, Merck Serono, Novartis, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche. Beratert\u00e4tigkeit: Ambu, Amgen, Apogepha, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Farco, Ferring Ipsen, Hexal, Sandoz, MedUpdate, MSD, Merck Serono, Novartis, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche. Forschungsf\u00f6rderung und Studien: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Ipsen, MSD, Merck Serono, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}